Q-omics provides the consensus-scored PDE4DIP profile across patient tissues and cancer cell-line models. PDE4DIP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDE4DIP is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, PDE4DIP RNA expression shows 19,550 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where PDE4DIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4DIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4DIP survival associations across molecular data types. PDE4DIP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4DIP RNA expression–survival associations across cancer types. High PDE4DIP expression shows unfavorable associations in UVM, HNSC, LAML, THYM and KICH, but favorable associations in SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDE4DIP RNA expression.
This table summarizes PDE4DIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE4DIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4DIP shows lower tumor expression in KIRC, KICH, LUSC and COAD and higher tumor expression in BLCA and LIHC. The BLCA box plot shows higher PDE4DIP RNA expression in tumor versus normal tissue (log2 FC = +0.630, t-test p < 0.001).
This table shows molecular features associated with PDE4DIP in patient tissues and cancer cell lines. In patient samples, PDE4DIP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE4DIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and CNS.
